Leucid Bio’s Post

Recruiting diverse participants for clinical trials is of high importance to ensure equitable healthcare. John Maher, Leucid Bio’s CSO, spoke to Richard Staines on the topic and believes that “by embracing diversity, we can bridge gaps in treatment accessibility and improve health outcomes for all. As leaders in biopharma, we must actively promote diversity in clinical trials to ensure that our medicines are effective across diverse populations." Read more about the discussion in the European Pharmaceutical Manufacturer article here: https://bit.ly/3VzBUPU.

Interesting ..

Leucid Bio and peers have published a research paper in Molecular Therapy showing a simple strategy to safely harness the armouring effects of interleukin (IL)18.   The group have tightly coupled the biological activity of IL18 to the activation state of the host CAR T-cell by the introduction of a granzyme B-dependent activation step and believe the use of this stringent system will be applicable in many experimental CAR T-cell immunotherapy approaches for cancer.   Read the full paper and learn more about how Leucid Bio is developing the next generation of CAR-T cells for hard-to-treat cancers using the links in the comments below.   Molecular Therapy is dedicated to publishing peer-reviewed research and cutting-edge reviews and commentaries promoting the sciences in #genetics, medicine and #biotechnology and is the founding journal of The American Society of Gene & Cell Therapy's official family of journals distributed by Cell Press   #GeneandCellTherapy #CARTcellTherapy 

Our CSO John Maher joins The Naked Scientists podcast to discuss ways in which we can harness the power of the body’s own immune system to develop first-in-class #cancer treatments.   At Leucid Bio, we are developing CAR T therapies to improve treatment outcomes for patients with refractory cancers.   📣Listen in on the ‘Tackling Cancers’ podcast episode here: https://bit.ly/4bpOtlJ   #CarTcellTherapy #CARTCR

Our CSO John Maher will be at the Cambridge Healthtech Institutes’ 8th Annual Immuno-Oncology Summit Europe 2024, chairing the afternoon session on Engineered T-cells commencing at 1:55pm today.   Tomorrow, John will present an update on LEU011, Leucid Bio’s lead asset, during the morning session on Novel Approaches Targeting Solid Tumours.   📣Presentation Title: Updates on LEU011: An Adaptor CAR Platform 🎙 Track: Next Generation Cell-Based Immunotherapies 📅 Presentation Date & Time: 25th April 2024 at 8:35am BST   #LEU011, an autologous, lateral CAR T cell therapy targeting NKG2D ligands, has the potential to treat multiple cancer indications as NKG2D ligands are reported to be expressed on more than 80% of human tumours.    Get in touch if you would like to connect at the #IOSummit to learn more about how Leucid Bio is developing next-generation cell therapies for hard-to-treat solid tumours utilising its proprietary Lateral CAR platform.   This year, the IO Summit Europe, a premier event for immuno-oncology professionals who want to learn about the latest advancements and innovations in the field, is taking place in London, one of the world’s leading hubs for biomedical research and clinical development.   #CarTCellTherapy #CARTCR #CGT #immunooncology

📣 Listen in as our CSO John Maher joins a panel of key industry leaders to provide insight into Clinical Trial Recruitment on the latest episode of the #optimumperspectives podcast hosted by Richard Staines   Learn more about Leucid's mission to develop the next generation of CAR-T therapies for refractory cancers using the link in the first comment below. Listen to the episode here: https://bit.ly/3TNhPDu   #CarTcellTherapy #CARTCR

Leucid Bio and peers have published a research paper in the peer-reviewed journal, MDPI Biology. The findings show the tumour recognition capacity of a T-cell receptor found in δγ T-cells can be expanded to allow it to recognise a second cancer target known as αvβ6 integrin.   It’s hoped this technique could lead to cancer cell therapies that are harder for tumours to resist– and there’s also the possibility of making other receptors recognise different combinations of cancer cell targets.   Read the full article and learn more about how Leucid Bio is developing the next generation of CAR-T cells for hard-to-treat cancers using the links in the comments below.   #CARTcellTherapy